Clinical Trial

A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will evaluate the dosimetry, safety, efficacy, pharmacokinetics (PK), pharmacodynamics and immunogenicity of CEA-PRIT 2.0 in participants with metastatic microsatellite-stable (MSS) mCRC who are intolerant to or have progressed after having received available standard-of-care (SOC) therapies.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-08-11
critical Trial status changed: Recruiting → Not Yet Recruiting 2026-07-08
critical Recruitment opened 2026-04-15
Trial Details
NCT Number NCT07416552
Lead Sponsor Hoffmann-La Roche
Conditions Metastatic Colorectal Cancer
Enrollment 180 participants
Start Date 2026-09-08
Primary Completion 2034-02-12 (estimated)
Study Completion 2034-02-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-10